Multicenter Database of Patients With Germ Cell Tumor
1 other identifier
observational
1,315
1 country
4
Brief Summary
Retrospective and prospective cohort of patients with germ cell tumor in treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2016
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 7, 2016
CompletedFirst Posted
Study publicly available on registry
August 11, 2016
CompletedStudy Start
First participant enrolled
September 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedDecember 27, 2021
August 1, 2021
3.2 years
July 7, 2016
December 23, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Brazilian multicenter database in order to collect and analyze data from diagnosis and treatment of patients with germ cell tumor
From 2000 to 2025
Secondary Outcomes (12)
Description of demographic characteristics of testicular germ cell tumor patients in Brazil
From 2000 to 2025
The clinical and pathological characteristics of testicular germ cell tumor patients in Brazil.
From 2000 to 2025
Treatment according to staging and relapse of patients diagnosed with testicular germ cell tumor in Brazil
From 2000 to 2025
Disease free survival of patients diagnosed with germ cell tumor stage 1.
From 2000 to 2025
Overall survival of patients diagnosed with germ cell tumor stage 1.
From 2000 to 2025
- +7 more secondary outcomes
Eligibility Criteria
Men with diagnosis of testicular, retroperitonium or mediastinal primary tumor.
You may qualify if:
- Male patients with diagnosis of testicular, retroperitoneum or mediastinal primary tumor.
- Histological confirmation of germ cell tumor or clinical condition based on the elevation of tumor markers (AFP, HCG e/ou DHL) associated to testicular mass or/and retroperitoneal lymphnode enlargement or/and mediastinal mass.
- Medical records of the disease and treatment
You may not qualify if:
- Female patients diagnosed with ovary germ cell tumor
- Male patients diagnosed with germ cell tumor in other locations.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
CPO - Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Israelita Albert Einstein
São Paulo, Brazil
Hospital São José
São Paulo, Brazil
ICESP
São Paulo, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Gustavo Werutsky, MD
Latin American Cooperative Oncology Group
- PRINCIPAL INVESTIGATOR
Diogo Bastos, MD
Instituto do Cancer do Estado de São Paulo
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 16 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 7, 2016
First Posted
August 11, 2016
Study Start
September 1, 2016
Primary Completion
December 1, 2019
Study Completion
December 1, 2020
Last Updated
December 27, 2021
Record last verified: 2021-08